RxDoctor Payments Data

Travis Zimbelman

Primary Podiatric Medicine · Montgomery, ALNPI 1013179621

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Boston Scientific at 28.5% of the total. 2025 is the largest year on record at $392, 2.0 times the $193 reported in 2019.

$1,340in general payments, 2019–2025

Across 34 payments — averaging $39.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$382
  • Stryker$273
  • Amgen$180
  • Johnson & Johnson$106
  • Vaporox, Inc.$106
  • Paratek Pharmaceuticals, Inc.$86
  • plus $207 from 7 others

What the payments were for

  • Food & beverage$1,340100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific8$382
Stryker(2 entities)4$273
Amgen(2 entities)4$180
Johnson & Johnson1$106
Vaporox, Inc.1$106
Paratek Pharmaceuticals, Inc.5$86
Bioventus LLC4$71
Trice Medical, Inc.2$59
Melinta Therapeutics, LLC1$20
Kerecis Limited1$19
Zyla Life Sciences, Inc.1$14
Kowa Pharmaceuticals America, Inc.1$13
Acera Surgical, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few primary podiatric medicine providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$335,416
Medicare patients
216
Services billed
1,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketoconazole414$13,838
Amitriptyline Hcl154$2,054
Diclofenac Sodium81$1,815
Gabapentin170$1,401
SsdSilver Sulfadiazine58$1,095
Terbinafine Hcl67$1,027
Duloxetine Hcl36$1,022
Pregabalin58$941
Celecoxib37$813
Imiquimod15$713
Cephalexin52$695
Methylprednisolone58$524
Ciprofloxacin Hcl15$322
Etodolac12$249
Silver Sulfadiazine15$227

Paid to pharmacies, not to this prescriber.

Other primary podiatric medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →